Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Catalent

Catalent Inc plans to expand its COVID-19 vaccine production in Europe that will enable it to make more doses of Johnson & Johnson's shot, the Wall Street Journal reported https://www.wsj.com/articles/catalent-to-expand-production-of-j-j-covid-19-vaccine-in-italy-11615941463?mod=latest_headlines on Tuesday, citing people familiar with the matter.

Catalent plans to expand production of J&J COVID-19 vaccine in Italy: WSJ

Avantis U.S. Small Cap Value ETF

iShares S&P Small-Cap 600 Value ETF

Novavax

SPDR S&P 600 Small Cap Value ETF

Vanguard Russell 2000 Value ETF

The U.S. small-cap index the Russell 2000 has outperformed its bigger peer equity gauges by wide margin this year.

A Guide to Small-Cap Value ETF Investing

J&J's (JNJ) shares are up this year mainly due to successful development of its COVID-19 vaccine.

J&J (JNJ) Outperforms the Industry Year to Date: Here's Why

It was a strong week for stocks, and we have a big week ahead with a critical Fed meeting on the horizon. Meanwhile, Q.ai's Artificial Intelligence has brought you this week's trending stocks.

Johnson & Johnson Among Trending Stocks For Second Week In A Row

J&J's (JNJ) single-shot COVID-19 vaccine gets Emergency Use Listing by the WHO, which will enable it to supply its vaccine to over 190 countries through COVAX facility.

J&J (JNJ) COVID-19 Vaccine Gets WHO's Emergency Listing

American Express

Caterpillar

Cisco Systems

Disney

JPMorgan Chase & Co

Lovesac Company

Tidewater

UnitedHealth Group

Walgreens

Two new breakout stocks for Week 11 of 2021 with better than 10% short-term upside potential. This past week both DSSI +11.4% and JNCE +27.1% gained more than 10% while the average return to the close for all 4 selections was a gain of +6.09%.

Week 11 MDA Breakout Stocks - March 2021: Short-Term Picks To Give You An Edge

BioNTech SE

Moderna

Pfizer

Don't jump to any conclusions based on the different vaccines' advisory committee votes.

Is Johnson & Johnson's COVID Vaccine Actually Better Than Pfizer's and Moderna's Vaccines?

The approval greenlights Johnson & Johnson's vaccine to start reaching dozens of low- and middle-income countries.

WHO Approves Johnson & Johnson's Covid Vaccine As Developing Countries Lag In Immunizations

COMPASS Pathways

Illumina

ResMed

Teladoc

Thermo Fisher Scientific

These steady, strong healthcare stocks are great picks for investors to buy and hold onto for at least the next five years. The post 7 Healthcare Stocks to Buy and Hold for the Long Term appeared first on InvestorPlace.

7 Healthcare Stocks to Buy and Hold for the Long Term

The World Health Organization on Friday granted emergency use authorization to the COVID-19 vaccine developed by Johnson & Johnson and added it to its Covax program, which aims to ensure vaccine equity for lower income countries. "Every new, safe and effective tool against COVID-19 is another step closer to controlling the pandemic," said WHO Director-General, Dr Tedros Adhanom Ghebreyesus.

World Health Organization grants emergency use authorization to Johnson & Johnson vaccine

NEW BRUNSWICK, N.J., March 12, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the World Health Organization (WHO) has issued Emergency Use Listing (EUL) for its single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), to prevent COVID-19 in individuals 18 years of age and older.

Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Emergency Use Listing by the World Health Organization

J&J's (JNJ) single-shot COVID-19 vaccine set to be available in Europe from April.

J&J (JNJ) COVID-19 Vaccine Gets Conditional Approval in Europe

JNJ is rapidly negotiating COVID-19 supply agreements with the Biden administration. JNJ's emergence could mean less 2021 COVID-19 supply for MRNA and NVAX whose valuations hinge on vaccine revenue.

Johnson & Johnson's COVID-19 Vaccine Could Threaten Moderna, Novavax

How Does Johnson & Johnson's COVID Vaccine Approval Affect Moderna?

Co-Diagnostics

Fulgent Genetics

2020 was a wild run for the biotech sector, with COVID-19 dominating the headlines. What will happen this year?

Biotech Stocks: What Will 2021 Look Like?

Allstate

Kroger

Morgan Stanley

Procter & Gamble

Verizon

Value stocks have come back into focus as the U.S. economy recovers from the global pandemic and volatility shakes stock markets around the world. In this article, we look at seven of the best value stocks available today.

7 of the Best Value Stocks on the Market Today

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the European Commission (EC) has granted a Conditional Marketing Authorization (CMA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), to prevent COVID-19 in individuals 18 years of age and older. The CMA follows a Positive Opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human

Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Conditional Marketing Authorization by European Commission

The shot, which was recently approved in the U.S., is the first single dose vaccine to be approved in the EU.

EU Approves J&J Single-Shot Covid-19 Vaccine As The Bloc's Vaccination Crisis Rumbles On

Fidelity MSCI Consumer Discretionary ETF

First Trust Consumer Discretionary AlphaDEX Fund

Vanguard Consumer Discretionary ETF

Consumer Discretionary Select Sector SPDR Fund

The reopening of the U.S. economy, coronavirus vaccine rollout and additional stimulus are expected to increasingly drive investors toward the consumer discretionary sector.

Consumer Discretionary ETFs to Ride Stimulus & Vaccine Optimism

Dow Inc

Goldman Sachs

Travelers

From muted inflation to the US economy getting better, economically-sensitive stocks are gaining traction, and along with it the Dow. This calls for investing in stocks like Caterpillar (CAT) & Goldman Sachs (GS).

5 Top Blue Chip Stocks to Buy as Dow Breezes Past 32,000

The European Medical Agency has recommended conditional marketing approval for Johnson & Johnson's (NYSE: JNJ) single-dose COVID-19 vaccine for those over 18 years of age. The bloc seeks to speed up the sluggish inoculation campaign and boost its supplies of vaccines.

News for Johnson & Johnson Stock (JNJ)